Pipeline

Clinical Trials

Secura Bio is supporting several studies to investigate disease states and/or drug combinations that have not received approval from the FDA or other health authorities. The information presented below does not make any claims with regard to safety or efficacy. There are no guarantees that the outcomes of these studies will result in regulatory approval(s).

Panobinostat
StudyTherapeutic AreaPhaseStatus
PANORAMA 3 Long-term follow-up
NCT02654990
Relapsed / Refractory Multiple Myeloma2Fully Enrolled
Single-agent w/ HAART
NCT02471430
HIV2Enrolling
Single-agent
NCT02717455
Diffuse Intrinsic Pontine Glioma2Enrolling
Panobinostat + gemcitabine pre-ASBMT
NCT02506959
Refractory or Relapsed Refractory Multiple Myeloma2Enrolling
Study of Marizomib + Panobinostat for Children with DIPG
NCT04341311
Diffuse Intrinsic Pontine Glioma1Active, Not Enrolling
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
NCT01245179
Sickle Cell Disease1Active, Not Enrolling
A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
NCT04897880
Rhabdoid tumors2Active (Australia), Duke Enrollment Pending

Additional areas of interest for future study: Studies in Multiple Myeloma, Diffuse Midline Glioma, Uveal Melanoma and other Hematologic Malignancies and solid tumors with existing scientific rationale.

For further information contact Steve Stricker at sstricker@securabio.com.

Duvelisib
StudyTherapeutic AreaPhaseStatus
PRIMO Single-agent
NCT03372057
Relapsed and / or Refractory Peripheral T-cell Lymphoma2Fully Enrolled
TEMPO Intermittent dosing
NCT03961672
Relapsed and / or Refractory Chronic Lymphocytic
Leukemia
2Enrolling
Duvelisib + nivolumab
NCT03892044
Richter Syndrome or Transformed Follicular Lymphoma2Enrolling
Duvelisib + venetoclax
NCT03534323
Relapsed or Refractory CLL / SLL / RS2Enrolling
Duvelisib + romidepsin or bortezomib
NCT02783625
Peripheral T-cell Lymphoma1Enrolling
Duvelisib intermittent dosing
NCT03961672
CLL / SLL2Enrolling
Duvelisib post-transplant
NCT04331119
Indolent Non-Hodgkin Lymphoma2Enrolling
Duvelisib + nivolumab
NCT04652960
Mycosis Fungoides / Sezary Syndrome1Not Yet Enrolling

Additional areas of interest to the duvalisib development program include new combinations in CLL/SLL and iNHL; DLBCL; T-cell lymphomas; and select solid tumors. Combinations with CAR-Ts, BiTEs, immunotherapies, and other novel mechanisms of action in hematologic and solid malignancies are also under consideration.

For further information contact Debra Litwak at dlitwak@securabio.com.